Know Cancer

or
forgot password

Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients


Phase 2
18 Years
80 Years
Not Enrolling
Both
Metastatic Renal Cell Carcinoma

Thank you

Trial Information

Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients


Inclusion Criteria:



- histologically confirmed non-clear cell renal cell carcinoma

- confirmed metastatic sites

- no chemotherapy in history

Exclusion Criteria:

- metastases in CNS

- previous targeted therapy

- other tumor

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response rate

Outcome Time Frame:

12 months

Safety Issue:

No

Principal Investigator

Lev Demidov, MD, D.Sc.

Investigator Role:

Principal Investigator

Investigator Affiliation:

N.N. Blokhin Russian Cancer Research Center

Authority:

Russia: Ministry of Health of the Russian Federation

Study ID:

CRT-06.CAP

NCT ID:

NCT01182142

Start Date:

September 2007

Completion Date:

August 2010

Related Keywords:

  • Metastatic Renal Cell Carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location